Related Experiment Video
Updated: Aug 9, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Levodopa availability improves with progression of Parkinson's disease
Dirk Woitalla1, Oliver Goetze, Jeong I Kim
1Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstr. 56, 44791 Bochum, Germany.
Journal of Neurology
|May 2, 2006
Summary
Levodopa plasma levels increase with Parkinson's disease (PD) progression, suggesting improved drug availability in advanced stages. This may be due to enzyme changes or better duodenal absorption in Parkinson's disease patients.
Area of Science:
- Pharmacokinetics
- Neurodegenerative Diseases
- Drug Metabolism
Background:
- Previous studies noted varied levodopa degradation in Parkinson's disease (PD) patients' plasma.
- Levodopa pharmacokinetics differ across PD stages.
Purpose of the Study:
- To determine the relationship between levodopa plasma concentrations and Parkinson's disease (PD) severity.
- Investigate levodopa levels in relation to PD progression.
Main Methods:
- Administered water-soluble levodopa (100 mg) and benserazide (25 mg) to 50 PD patients off medication.
- Measured levodopa plasma concentrations over 180 minutes under standardized conditions.
Main Results:
- Area under the curve (AUC) for levodopa plasma levels was significantly higher in advanced PD patients.
- PD severity scores correlated significantly with AUC and maximum levodopa plasma concentration.
Conclusions:
- Levodopa bioavailability appears to increase as Parkinson's disease (PD) progresses.
- Potential mechanisms include reduced peripheral levodopa metabolism or enhanced duodenal absorption due to enteric dysfunction.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...